{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,29]],"date-time":"2026-07-29T00:42:55Z","timestamp":1785285775503,"version":"3.55.0"},"reference-count":40,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2020,6,1]],"date-time":"2020-06-01T00:00:00Z","timestamp":1590969600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2020,6,1]],"date-time":"2020-06-01T00:00:00Z","timestamp":1590969600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Ann Hematol"],"published-print":{"date-parts":[[2021,1]]},"DOI":"10.1007\/s00277-020-04094-3","type":"journal-article","created":{"date-parts":[[2020,6,2]],"date-time":"2020-06-02T14:05:25Z","timestamp":1591106725000},"page":"143-155","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":52,"title":["Atrial fibrillation in patients with chronic lymphocytic leukemia (CLL) treated with ibrutinib: risk prediction, management, and clinical outcomes"],"prefix":"10.1007","volume":"100","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-1498-5886","authenticated-orcid":false,"given":"William J.","family":"Archibald","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kari G.","family":"Rabe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brian F.","family":"Kabat","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joerg","family":"Herrmann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wei","family":"Ding","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Neil E.","family":"Kay","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Saad S.","family":"Kenderian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eli","family":"Muchtar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jose F.","family":"Leis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yucai","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Asher A.","family":"Chanan-Khan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Susan M.","family":"Schwager","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amber B.","family":"Koehler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amie L.","family":"Fonder","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Susan L.","family":"Slager","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tait D.","family":"Shanafelt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Timothy G.","family":"Call","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sameer A.","family":"Parikh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2020,6,1]]},"reference":[{"key":"4094_CR1","unstructured":"Howlader N NA, Krapcho M, Miller D, Bishop K, Kosary CL, Yu M, Ruhl J, Tatalovich Z, Mariotto A, Lewis DR, Chen HS, Feuer EJ, Cronin KA (eds). SEER Cancer Statistics Review, 1975-2014. Bethesda, MD: National Cancer Institute."},{"issue":"25","key":"4094_CR2","doi-asserted-by":"publisher","first-page":"2425","DOI":"10.1056\/NEJMoa1509388","volume":"373","author":"JA Burger","year":"2015","unstructured":"Burger JA, Tedeschi A, Barr PM, Robak T, Owen C, Ghia P, Bairey O, Hillmen P, Bartlett NL, Li J, Simpson D, Grosicki S, Devereux S, McCarthy H, Coutre S, Quach H, Gaidano G, Maslyak Z, Stevens DA, Janssens A, Offner F, Mayer J, O'Dwyer M, Hellmann A, Schuh A, Siddiqi T, Polliack A, Tam CS, Suri D, Cheng M, Clow F, Styles L, James DF, Kipps TJ, RESONATE-2 Investigators (2015 Dec 17) Ibrutinib as initial therapy for patients with chronic lymphocytic leukemia. N Engl J Med 373(25):2425\u20132437","journal-title":"N Engl J Med"},{"issue":"5","key":"4094_CR3","doi-asserted-by":"publisher","first-page":"432","DOI":"10.1056\/NEJMoa1817073","volume":"381","author":"TD Shanafelt","year":"2019","unstructured":"Shanafelt TD, Wang XV, Kay NE, Hanson CA, O\u2019Brien S, Barrientos J, Jelinek DF, Braggio E, Leis JF, Zhang CC, Coutre SE, Barr PM, Cashen AF, Mato AR, Singh AK, Mullane MP, Little RF, Erba H, Stone RM, Litzow M, Tallman M (2019 Aug 1) Ibrutinib-rituximab or chemoimmunotherapy for chronic lymphocytic leukemia. N Engl J Med 381(5):432\u2013443","journal-title":"N Engl J Med"},{"issue":"26","key":"4094_CR4","doi-asserted-by":"publisher","first-page":"2517","DOI":"10.1056\/NEJMoa1812836","volume":"379","author":"JA Woyach","year":"2018","unstructured":"Woyach JA, Ruppert AS, Heerema NA, Zhao W, Booth AM, Ding W, Bartlett NL, Brander DM, Barr PM, Rogers KA, Parikh SA, Coutre S, Hurria A, Brown JR, Lozanski G, Blachly JS, Ozer HG, Major-Elechi B, Fruth B, Nattam S, Larson RA, Erba H, Litzow M, Owen C, Kuzma C, Abramson JS, Little RF, Smith SE, Stone RM, Mandrekar SJ, Byrd JC (2018) Ibrutinib regimens versus chemoimmunotherapy in older patients with untreated CLL. N Engl J Med 379(26):2517\u20132528","journal-title":"N Engl J Med"},{"issue":"25","key":"4094_CR5","doi-asserted-by":"publisher","first-page":"3829","DOI":"10.1182\/blood-2014-10-604272","volume":"124","author":"JR McMullen","year":"2014","unstructured":"McMullen JR, Boey EJ, Ooi JY, Seymour JF, Keating MJ, Tam CS (2014 Dec 11) Ibrutinib increases the risk of atrial fibrillation, potentially through inhibition of cardiac PI3K-Akt signaling. Blood. 124(25):3829\u20133830","journal-title":"Blood."},{"issue":"3","key":"4094_CR6","doi-asserted-by":"publisher","first-page":"462","DOI":"10.1111\/bjh.14324","volume":"175","author":"PA Thompson","year":"2016","unstructured":"Thompson PA, Levy V, Tam CS, Al Nawakil C, Goudot FX, Quinquenel A et al (2016) Atrial fibrillation in CLL patients treated with ibrutinib. An international retrospective study. Br J Haematol 175(3):462\u2013466","journal-title":"Br J Haematol"},{"issue":"3","key":"4094_CR7","doi-asserted-by":"publisher","first-page":"213","DOI":"10.1056\/NEJMoa1400376","volume":"371","author":"JC Byrd","year":"2014","unstructured":"Byrd JC, Brown JR, O\u2019Brien S, Barrientos JC, Kay NE, Reddy NM et al (2014) Ibrutinib versus ofatumumab in previously treated chronic lymphoid leukemia. N Engl J Med 371(3):213\u2013223","journal-title":"N Engl J Med"},{"issue":"2","key":"4094_CR8","doi-asserted-by":"publisher","first-page":"200","DOI":"10.1016\/S1470-2045(15)00465-9","volume":"17","author":"A Chanan-Khan","year":"2016","unstructured":"Chanan-Khan A, Cramer P, Demirkan F, Fraser G, Silva RS, Grosicki S, Pristupa A, Janssens A, Mayer J, Bartlett NL, Dilhuydy MS, Pylypenko H, Loscertales J, Avigdor A, Rule S, Villa D, Samoilova O, Panagiotidis P, Goy A, Mato A, Pavlovsky MA, Karlsson C, Mahler M, Salman M, Sun S, Phelps C, Balasubramanian S, Howes A, Hallek M, HELIOS investigators (2016) Ibrutinib combined with bendamustine and rituximab compared with placebo, bendamustine, and rituximab for previously treated chronic lymphocytic leukaemia or small lymphocytic lymphoma (HELIOS): a randomised, double-blind, phase 3 study. Lancet Oncol 17(2):200\u2013211","journal-title":"Lancet Oncol"},{"issue":"1","key":"4094_CR9","doi-asserted-by":"publisher","first-page":"138","DOI":"10.1182\/blood-2016-05-712828","volume":"128","author":"DP Leong","year":"2016","unstructured":"Leong DP, Caron F, Hillis C, Duan A, Healey JS, Fraser G, Siegal D (2016) The risk of atrial fibrillation with ibrutinib use: a systematic review and meta-analysis. Blood. 128(1):138\u2013140","journal-title":"Blood."},{"issue":"21","key":"4094_CR10","doi-asserted-by":"publisher","first-page":"2357","DOI":"10.1182\/blood-2017-12-820910","volume":"131","author":"IE Ahn","year":"2018","unstructured":"Ahn IE, Farooqui MZH, Tian X, Valdez J, Sun C, Soto S, Lotter J, Housel S, Stetler-Stevenson M, Yuan CM, Maric I, Calvo KR, Nierman P, Hughes TE, Saba NS, Marti GE, Pittaluga S, Herman SEM, Niemann CU, Pedersen LB, Geisler CH, Childs R, Aue G, Wiestner A (2018) Depth and durability of response to ibrutinib in CLL: 5-year follow-up of a phase 2 study. Blood. 131(21):2357\u20132366","journal-title":"Blood."},{"issue":"20","key":"4094_CR11","doi-asserted-by":"publisher","first-page":"1739","DOI":"10.1182\/bloodadvances.2017009720","volume":"1","author":"TE Wiczer","year":"2017","unstructured":"Wiczer TE, Levine LB, Brumbaugh J, Coggins J, Zhao Q, Ruppert AS, Rogers K, McCoy A, Mousa L, Guha A, Heerema NA, Maddocks K, Christian B, Andritsos LA, Jaglowski S, Devine S, Baiocchi R, Woyach J, Jones J, Grever M, Blum KA, Byrd JC, Awan FT (2017) Cumulative incidence, risk factors, and management of atrial fibrillation in patients receiving ibrutinib. Blood Adv 1(20):1739\u20131748","journal-title":"Blood Adv"},{"issue":"10","key":"4094_CR12","doi-asserted-by":"publisher","first-page":"648","DOI":"10.1016\/j.clml.2018.06.016","volume":"18","author":"S O\u2019Brien","year":"2018","unstructured":"O\u2019Brien S, Hillmen P, Coutre S, Barr PM, Fraser G, Tedeschi A et al (2018) Safety analysis of four randomized controlled studies of ibrutinib in patients with chronic lymphocytic leukemia\/small lymphocytic lymphoma or mantle cell lymphoma. Clin Lymphoma Myeloma Leuk 18(10):648\u2013657 e15","journal-title":"Clin Lymphoma Myeloma Leuk"},{"issue":"6","key":"4094_CR13","doi-asserted-by":"publisher","first-page":"1447","DOI":"10.1080\/10428194.2018.1533129","volume":"60","author":"R Lentz","year":"2019","unstructured":"Lentz R, Feinglass J, Ma S, Akhter N (2019) Risk factors for the development of atrial fibrillation on ibrutinib treatment. Leuk Lymphoma 60(6):1447\u20131453","journal-title":"Leuk Lymphoma"},{"issue":"7","key":"4094_CR14","doi-asserted-by":"publisher","first-page":"1630","DOI":"10.1080\/10428194.2016.1257795","volume":"58","author":"TD Shanafelt","year":"2017","unstructured":"Shanafelt TD, Parikh SA, Noseworthy PA, Goede V, Chaffee KG, Bahlo J, Call TG, Schwager SM, Ding W, Eichhorst B, Fischer K, Leis JF, Chanan-Khan AA, Hallek M, Slager SL, Kay NE (2017) Atrial fibrillation in patients with chronic lymphocytic leukemia (CLL). Leuk Lymphoma 58(7):1630\u20131639","journal-title":"Leuk Lymphoma"},{"issue":"Suppl 1","key":"4094_CR15","doi-asserted-by":"publisher","first-page":"3118","DOI":"10.1182\/blood-2018-99-114899","volume":"132","author":"A Visentin","year":"2018","unstructured":"Visentin A, Deodato M, Mauro FR, Autore F, Reda G, Vitale C, Molica S, Rigolin GM, Imbergamo S, Scomazzon E, Pravato S, Frezzato F, Facco M, Piazza F, Cesini L, Tedeschi A, Laurenti L, Cortelezzi A, Coscia M, Cuneo A, Fo\u00e0 R, Semenzato G, Trentin LA (2018) Scoring system to predict the risk of atrial fibrillation in chronic lymphocytic leukemia and its validation in a cohort of ibrutinib-treated patients. Blood 132(Suppl 1):3118","journal-title":"Blood"},{"issue":"12","key":"4094_CR16","doi-asserted-by":"publisher","first-page":"1491","DOI":"10.1016\/j.jacep.2018.06.004","volume":"4","author":"S Ganatra","year":"2018","unstructured":"Ganatra S, Sharma A, Shah S, Chaudhry GM, Martin DT, Neilan TG et al (2018) Ibrutinib-associated atrial fibrillation. JACC Clin Electrophysiol 4(12):1491\u20131500","journal-title":"JACC Clin Electrophysiol"},{"key":"4094_CR17","first-page":"1","volume":"7","author":"R Lentz","year":"2019","unstructured":"Lentz R, Feinglass J, Ma S, Akhter N (2019) Risk factors for the development of atrial fibrillation on ibrutinib treatment. Leuk Lymphoma 7:1\u20137","journal-title":"Leuk Lymphoma"},{"issue":"5","key":"4094_CR18","first-page":"e2701","volume":"10","author":"S Khalid","year":"2018","unstructured":"Khalid S, Yasar S, Khalid A, Spiro TP, Haddad A, Daw H (2018) Management of atrial fibrillation in patients on ibrutinib: a Cleveland Clinic experience. Cureus. 10(5):e2701","journal-title":"Cureus."},{"issue":"1","key":"4094_CR19","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1186\/s13045-018-0626-0","volume":"11","author":"G Reda","year":"2018","unstructured":"Reda G, Fattizzo B, Cassin R, Mattiello V, Tonella T, Giannarelli D, Massari F, Cortelezzi A (2018) Predictors of atrial fibrillation in ibrutinib-treated CLL patients: a prospective study. J Hematol Oncol 11(1):79","journal-title":"J Hematol Oncol"},{"issue":"4","key":"4094_CR20","doi-asserted-by":"publisher","first-page":"624","DOI":"10.1002\/hon.2503","volume":"36","author":"G Boriani","year":"2018","unstructured":"Boriani G, Corradini P, Cuneo A, Falanga A, Fo\u00e0 R, Gaidano G, Ghia PP, Martelli M, Marasca R, Massaia M, Mauro FR, Minotti G, Molica S, Montillo M, Pinto A, Tedeschi A, Vitolo U, Zinzani PL (2018) Practical management of ibrutinib in the real life: focus on atrial fibrillation and bleeding. Hematol Oncol 36(4):624\u2013632","journal-title":"Hematol Oncol"},{"issue":"13","key":"4094_CR21","doi-asserted-by":"publisher","first-page":"1667","DOI":"10.1016\/j.jacc.2019.07.056","volume":"74","author":"JE Salem","year":"2019","unstructured":"Salem JE, Manouchehri A, Bretagne M, Lebrun-Vignes B, Groarke JD, Johnson DB, Yang T, Reddy NM, Funck-Brentano C, Brown JR, Roden DM, Moslehi JJ (2019) Cardiovascular toxicities associated with ibrutinib. J Am Coll Cardiol 74(13):1667\u20131678","journal-title":"J Am Coll Cardiol"},{"issue":"12","key":"4094_CR22","doi-asserted-by":"publisher","first-page":"1298","DOI":"10.1182\/blood-2018-11-846808","volume":"133","author":"DM Stephens","year":"2019","unstructured":"Stephens DM, Byrd JC (2019) How I manage ibrutinib intolerance and complications in patients with chronic lymphocytic leukemia. Blood. 133(12):1298\u20131307","journal-title":"Blood."},{"issue":"3","key":"4094_CR23","doi-asserted-by":"publisher","first-page":"338","DOI":"10.1002\/ajh.25385","volume":"94","author":"H Fang","year":"2019","unstructured":"Fang H, Reichard KK, Rabe KG, Hanson CA, Call TG, Ding W, Kenderian SS, Muchtar E, Schwager SM, Leis JF, Chanan-Khan AA, Slager SL, Braggio E, Smoley SA, Kay NE, Shanafelt TD, van Dyke DL, Parikh SA (2019) IGH translocations in chronic lymphocytic leukemia: clinicopathologic features and clinical outcomes. Am J Hematol 94(3):338\u2013345","journal-title":"Am J Hematol"},{"issue":"3","key":"4094_CR24","doi-asserted-by":"publisher","first-page":"421","DOI":"10.1111\/bjh.15545","volume":"183","author":"PJ Hampel","year":"2018","unstructured":"Hampel PJ, Larson MC, Kabat B, Call TG, Ding W, Kenderian SS, Bowen D, Boysen J, Schwager SM, Leis JF, Chanan-Khan AA, Muchtar E, Hanson CA, Slager SL, Kay NE, Chaffee KG, Shanafelt TD, Parikh SA (2018) Autoimmune cytopenias in patients with chronic lymphocytic leukaemia treated with ibrutinib in routine clinical practice at an academic medical centre. Br J Haematol 183(3):421\u2013427","journal-title":"Br J Haematol"},{"issue":"6","key":"4094_CR25","doi-asserted-by":"publisher","first-page":"774","DOI":"10.1111\/bjh.12458","volume":"162","author":"SA Parikh","year":"2013","unstructured":"Parikh SA, Rabe KG, Call TG, Zent CS, Habermann TM, Ding W, Leis JF, Schwager SM, Hanson CA, Macon WR, Kay NE, Slager SL, Shanafelt TD (2013) Diffuse large B-cell lymphoma (Richter syndrome) in patients with chronic lymphocytic leukaemia (CLL): a cohort study of newly diagnosed patients. Br J Haematol 162(6):774\u2013782","journal-title":"Br J Haematol"},{"key":"4094_CR26","doi-asserted-by":"publisher","first-page":"247","DOI":"10.1016\/j.ejca.2017.06.028","volume":"83","author":"S Ugurel","year":"2017","unstructured":"Ugurel S, Rohmel J, Ascierto PA, Flaherty KT, Grob JJ, Hauschild A et al (2017) Survival of patients with advanced metastatic melanoma: the impact of novel therapies-update 2017. Eur J Cancer 83:247\u2013257","journal-title":"Eur J Cancer"},{"issue":"2","key":"4094_CR27","doi-asserted-by":"publisher","first-page":"263","DOI":"10.1378\/chest.09-1584","volume":"137","author":"GY Lip","year":"2010","unstructured":"Lip GY, Nieuwlaat R, Pisters R, Lane DA, Crijns HJ (2010) Refining clinical risk stratification for predicting stroke and thromboembolism in atrial fibrillation using a novel risk factor-based approach: the euro heart survey on atrial fibrillation. Chest. 137(2):263\u2013272","journal-title":"Chest."},{"issue":"4","key":"4094_CR28","doi-asserted-by":"publisher","first-page":"692","DOI":"10.1111\/j.1538-7836.2005.01204.x","volume":"3","author":"S Schulman","year":"2005","unstructured":"Schulman S, Kearon C (2005) Subcommittee on control of anticoagulation of the S, Standardization Committee of the International Society on T, Haemostasis. Definition of major bleeding in clinical investigations of antihemostatic medicinal products in non-surgical patients. J Thromb Haemost 3(4):692\u2013694","journal-title":"J Thromb Haemost"},{"issue":"11","key":"4094_CR29","doi-asserted-by":"publisher","first-page":"2119","DOI":"10.1111\/jth.13140","volume":"13","author":"S Kaatz","year":"2015","unstructured":"Kaatz S, Ahmad D, Spyropoulos AC, Schulman S (2015) Subcommittee on Control of A. Definition of clinically relevant non-major bleeding in studies of anticoagulants in atrial fibrillation and venous thromboembolic disease in non-surgical patients: communication from the SSC of the ISTH. J Thromb Haemost 13(11):2119\u20132126","journal-title":"J Thromb Haemost"},{"issue":"11","key":"4094_CR30","doi-asserted-by":"publisher","first-page":"981","DOI":"10.1056\/NEJMoa1107039","volume":"365","author":"CB Granger","year":"2011","unstructured":"Granger CB, Alexander JH, McMurray JJ, Lopes RD, Hylek EM, Hanna M, al-Khalidi HR, Ansell J, Atar D, Avezum A, Bahit MC, Diaz R, Easton JD, Ezekowitz JA, Flaker G, Garcia D, Geraldes M, Gersh BJ, Golitsyn S, Goto S, Hermosillo AG, Hohnloser SH, Horowitz J, Mohan P, Jansky P, Lewis BS, Lopez-Sendon JL, Pais P, Parkhomenko A, Verheugt FW, Zhu J, Wallentin L, ARISTOTLE Committees and Investigators (2011) Apixaban versus warfarin in patients with atrial fibrillation. N Engl J Med 365(11):981\u2013992","journal-title":"N Engl J Med"},{"issue":"12","key":"4094_CR31","doi-asserted-by":"publisher","first-page":"1139","DOI":"10.1056\/NEJMoa0905561","volume":"361","author":"SJ Connolly","year":"2009","unstructured":"Connolly SJ, Ezekowitz MD, Yusuf S, Eikelboom J, Oldgren J, Parekh A, Pogue J, Reilly PA, Themeles E, Varrone J, Wang S, Alings M, Xavier D, Zhu J, Diaz R, Lewis BS, Darius H, Diener HC, Joyner CD, Wallentin L, RE-LY Steering Committee and Investigators (2009) Dabigatran versus warfarin in patients with atrial fibrillation. N Engl J Med 361(12):1139\u20131151","journal-title":"N Engl J Med"},{"issue":"23","key":"4094_CR32","first-page":"e199","volume":"130","author":"CT January","year":"2014","unstructured":"January CT, Wann LS, Alpert JS, Calkins H, Cigarroa JE, Cleveland JC Jr et al (2014) 2014 AHA\/ACC\/HRS guideline for the management of patients with atrial fibrillation: a report of the American College of Cardiology\/American Heart Association Task Force on practice guidelines and the Heart Rhythm Society. Circulation. 130(23):e199\u2013e267","journal-title":"Circulation."},{"issue":"19","key":"4094_CR33","doi-asserted-by":"publisher","first-page":"2298","DOI":"10.1161\/CIRCULATIONAHA.111.055079","volume":"125","author":"L Friberg","year":"2012","unstructured":"Friberg L, Rosenqvist M, Lip GY (2012) Net clinical benefit of warfarin in patients with atrial fibrillation: a report from the Swedish atrial fibrillation cohort study. Circulation. 125(19):2298\u20132307","journal-title":"Circulation."},{"issue":"10","key":"4094_CR34","doi-asserted-by":"publisher","first-page":"883","DOI":"10.1056\/NEJMoa1009638","volume":"365","author":"MR Patel","year":"2011","unstructured":"Patel MR, Mahaffey KW, Garg J, Pan G, Singer DE, Hacke W, Breithardt G, Halperin JL, Hankey GJ, Piccini JP, Becker RC, Nessel CC, Paolini JF, Berkowitz SD, Fox KAA, Califf RM, the ROCKET AF Steering Committee (2011) Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. N Engl J Med 365(10):883\u2013891","journal-title":"N Engl J Med"},{"issue":"4","key":"4094_CR35","doi-asserted-by":"publisher","first-page":"783","DOI":"10.1038\/leu.2014.247","volume":"29","author":"S Kamel","year":"2015","unstructured":"Kamel S, Horton L, Ysebaert L, Levade M, Burbury K, Tan S, Cole-Sinclair M, Reynolds J, Filshie R, Schischka S, Khot A, Sandhu S, Keating MJ, Nandurkar H, Tam CS (2015) Ibrutinib inhibits collagen-mediated but not ADP-mediated platelet aggregation. Leukemia. 29(4):783\u2013787","journal-title":"Leukemia."},{"issue":"26","key":"4094_CR36","doi-asserted-by":"publisher","first-page":"3991","DOI":"10.1182\/blood-2014-06-583294","volume":"124","author":"M Levade","year":"2014","unstructured":"Levade M, David E, Garcia C, Laurent PA, Cadot S, Michallet AS, Bordet JC, Tam C, Si\u00e9 P, Ysebaert L, Payrastre B (2014) Ibrutinib treatment affects collagen and von Willebrand factor-dependent platelet functions. Blood. 124(26):3991\u20133995","journal-title":"Blood."},{"issue":"12","key":"4094_CR37","doi-asserted-by":"publisher","first-page":"1571","DOI":"10.3324\/haematol.2015.126672","volume":"100","author":"AH Lipsky","year":"2015","unstructured":"Lipsky AH, Farooqui MZ, Tian X, Martyr S, Cullinane AM, Nghiem K et al (2015) Incidence and risk factors of bleeding-related adverse events in patients with chronic lymphocytic leukemia treated with ibrutinib. Haematologica. 100(12):1571\u20131578","journal-title":"Haematologica."},{"issue":"2","key":"4094_CR38","doi-asserted-by":"publisher","first-page":"286","DOI":"10.1111\/bjh.14660","volume":"178","author":"JA Jones","year":"2017","unstructured":"Jones JA, Hillmen P, Coutre S, Tam C, Furman RR, Barr PM, Schuster SJ, Kipps TJ, Flinn IW, Jaeger U, Burger JA, Cheng M, Ninomoto J, James DF, Byrd JC, O'Brien SM (2017) Use of anticoagulants and antiplatelet in patients with chronic lymphocytic leukaemia treated with single-agent ibrutinib. Br J Haematol 178(2):286\u2013291","journal-title":"Br J Haematol"},{"issue":"10","key":"4094_CR39","doi-asserted-by":"publisher","first-page":"1796","DOI":"10.3324\/haematol.2017.171041","volume":"102","author":"JR Brown","year":"2017","unstructured":"Brown JR, Moslehi J, O'Brien S, Ghia P, Hillmen P, Cymbalista F et al (2017) Characterization of atrial fibrillation adverse events reported in ibrutinib randomized controlled registration trials. Haematologica. 102(10):1796\u20131805","journal-title":"Haematologica."},{"issue":"12","key":"4094_CR40","doi-asserted-by":"publisher","first-page":"1107","DOI":"10.1056\/NEJMoa1713976","volume":"378","author":"JF Seymour","year":"2018","unstructured":"Seymour JF, Kipps TJ, Eichhorst B, Hillmen P, D\u2019Rozario J, Assouline S, Owen C, Gerecitano J, Robak T, de la Serna J, Jaeger U, Cartron G, Montillo M, Humerickhouse R, Punnoose EA, Li Y, Boyer M, Humphrey K, Mobasher M, Kater AP (2018) Venetoclax-rituximab in relapsed or refractory chronic lymphocytic leukemia. N Engl J Med 378(12):1107\u20131120","journal-title":"N Engl J Med"}],"container-title":["Annals of Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00277-020-04094-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00277-020-04094-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00277-020-04094-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,6,1]],"date-time":"2021-06-01T01:18:08Z","timestamp":1622510288000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00277-020-04094-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,6,1]]},"references-count":40,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2021,1]]}},"alternative-id":["4094"],"URL":"https:\/\/doi.org\/10.1007\/s00277-020-04094-3","relation":{"has-review":[{"id-type":"doi","id":"10.3410\/f.738074929.793582673","asserted-by":"object"}]},"ISSN":["0939-5555","1432-0584"],"issn-type":[{"value":"0939-5555","type":"print"},{"value":"1432-0584","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,6,1]]},"assertion":[{"value":"1 December 2019","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 May 2020","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 June 2020","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The Mayo Clinic Institutional Review Board approved this study and all patients consented to the use of their medical records for research purposes.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"SAP: Research funding has been provided to the institution from Pharmacyclics, MorphoSys, Janssen, AstraZeneca, AbbVie, TG Therapeutics, and Ascentage Pharma for clinical studies in which Sameer A. Parikh is a principal investigator. Sameer A. Parikh has also participated in Advisory Board meetings of Pharmacyclics, AstraZeneca, Genentech, Gilead, Verastem Oncology and AbbVie (he was not personally compensated for his participation). NEK: Research funding has been provided to the institution from Pharmacyclics, Acerta, Tolero & MEI Pharma for which Neil E. Kay is a principal investigator. Dr. Kay has also participated as a member of the Data and Safety Monitoring Board for Cytomx Therapeutics, Infinity Pharm, Agios Pharm, Celgene, and MorphoSys. He has also participated in Advisory Board meetings of Pharmacyclics and Janssen. WD: Research funding has been provided to the institution from Merck for which Wei Ding is a principal investigator. SSK: Sponsored Research Funding provided to the laboratory from Novartis, Kite, Actinium, MorphoSys, Lentigen, Humanigen, and Tolero. SSK is inventor on patents licensed to Novartis and Humanigen. SSK is a co-founder of Leah Labs and SensImmune and he has participated as a consultant to Leah Labs and Kiniksa. TDS: Research funding has been provided to the institution from Pharmacyclics, Janssen, Genentech, GlaxoSmithKline, Celgene, Cephalon, and Hospira for which Tait D. Shanafelt is a principal investigator. All other authors have no conflict of interest to report.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interest"}}]}}